HECTD2

Across TCGA pan-cancer cohorts, HECTD2 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of HECTD2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney chromophobe (KICH), where HECTD2 RNA is repressed in tumor relative to normal tissue. In most cancer types HECTD2 is over-expressed in tumor, although a few such as KICH and BLCA show the opposite, repressed pattern.

KICH, BLCA, and LIHC are the cancer types where HECTD2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HECTD2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KICH	Female	All	−1.247	<.001	8	view →
BLCA	All	All	−0.771	.001	8	view →
LIHC	Female	II,III,IV	+0.601	<.001	8	view →
COAD	All	II,III,IV	−0.432	<.001	7	view →
UCEC	All	All	−1.113	<.001	6	view →
CHOL	All	All	+1.501	<.001	3	view →
LUSC	All	All	−0.227	.006	3	view →
PRAD	All	All	−0.645	<.001	2	view →
HNSC	Female	All	+0.314	.040	2	view →
KIRC	All	All	+0.217	.011	2	view →
READ	All	All	−0.743	.030	1	view →
THCA	All	II,III,IV	−0.286	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

HECTD2–KICH

Open the KICH breakdown →